In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia.
The in vitro and in vivo activities of azithromycin against chlamydia were investigated. The MIC of azithromycin for five standard strains of different species of chlamydia and six wild-type strains of Chlamydia pneumoniae was 0.125 microgram/ml, which was superior to that of erythromycin but inferior to those of clarithromycin and minocycline. However, the therapeutic effect of a 7-day course of azithromycin at a dose of 10 mg/kg of body weight administered orally once daily to mice with experimental Chlamydia psittaci pneumonia was excellent, with a 100% survival rate at 14 days after infection, which was the same as that for treatment with minocycline administered at 10 mg/kg twice daily; all erythromycin treated animals died within 10 days. When treatment was discontinued 3 days after the infection, the survival rate for mice treated with azithromycin was 90% and that for mice administered minocycline was 30%. These results suggest that azithromycin may be useful in the treatment of respiratory infections caused by intracellular pathogens, including chlamydia because of its excellent accumulation within host cells.
Department of Medicine, Kawasaki Medical School, Japan.
Y
Y
Niki
M
M
Kimura
N
N
Miyashita
R
R
Soejima
D000818:Animals; D017963:Azithromycin / Q000494:pharmacology* / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000188:drug therapy*; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D002691:Chlamydophila psittaci / Q000187:drug effects*; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests
D017963:Azithromycin